Malignant pheochromocytomas are rare in childhood and the prognosis of children with this tumor is not well known. We present 2 pediatric observations of malignant pelvic pheochromocytoma. Symptoms in both cases were headache and hypertension. The tumor invaded the sacral bone. Angiogram helped to localize the tumor and metastases, and allowed preoperative embolization of the tumor in 1 case. The first child underwent incomplete surgical resection, 131I-MIBG therapy and radiotherapy, and is still alive 2 years after diagnosis. The second child died from metastatic invasion a few weeks after discovery of the tumor. We reviewed previous reports of children with malignant pheochromocytomas (30 cases). Primary tumor was extraadrenal in 50% of cases. The 3-year survival rate was 73 ± 9% (mean ± SD). Apart from surgical resection, no particular treatment appeared to be more effective than others in reducing mortality.

Keywords:
Malignant pheochromocytoma, Children, Prognosis, pheochromocytoma, Treatment, pheochromocytoma
1.
Werbel SS, Ober KP: Pheochromocytoma. Update on diagnosis, localization and management. Med Clin North Am 1995;79:131–153.
2.
Deal JE, Sever PS, Barrat TM, Dillon MJ: Phaeochromocytoma-investigation and management of 10 cases. Arch Dis Child 1990;65:269–274.
3.
Wyszynska T, Cichocka E, Wieteska-Klimezak A, Jobs K, Januszewicz P: A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992;81:244–246.
4.
Scott HW, Halter SA: Oncologic aspects of pheochromocytoma: The importance of follow-up. Surgery 1984;96:1061–1065.
5.
Mahonney EM, Harrison JH: Malignant pheochromocytoma: Clinical course and treatment. J Urol 1977;118:225–229.
6.
James RE, Baker HL, Scanlon PW: The roentgenologic aspects of metastatic pheochromocytoma. Am J Roentgenol Radium Ther Nucl Med 1972;115:783–793.
7.
Stackpole RH, Melicow MM, Uson AC: Pheochromocytoma in children. J Pediatr 1963;63:315–330.
8.
Cone TE, Pearson HA: Malignant pheochromocytoma. Pediatrics 1963;32:531–539.
9.
Boreus LO, Broberger U, Nergardh A, Zetterqvist P: Malignant pheochromocytoma in a child: Treatment with a combination of alpha and beta adrenergic blockade. Acta Paediatr Scand 1968;57:36–40.
10.
Castelman B, Scully RE, McNeely BU: Case records of the Massachusetts General Hospital. N Engl J Med 1973;288:1010–1018.
11.
Lorenzo RL: Malignant recurrent extra-adrenal pheochromocytoma in a child. Pediatr Radiol 1977;5:175–177.
12.
Ein SH, Weitzman S, Thorner P, Seagram CG, Filler RM: Pediatric malignant pheochromocytoma. J Pediatr Surg 1994;29:1197–1201.
13.
Kaufman BH, Telander RL, van Heerden JA, Zimmerman D, Sheps SG, Dawson B: Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 1983;18:879–883.
14.
Pickard JL, Ross G, Silver D: Coexisting extraadrenal pheochromocytoma and renal artery stenosis : A case report and review of the pathophysiology. J Pediatr Surg 1995;30:1613–1615.
15.
Phillips AF, McMurtry RJ, Taubman J: Malignant pheochromocytoma in childhood. Am J Dis Child 1976;130:1252–1255.
16.
Meyer JJ, Sane SM, Drake RM: Malignant paraganglioma of the urinary bladder: Report of a case and review of the literature. Pediatrics 1979;63:879–885.
17.
Scott WW, Eversole SL: Pheochromocytoma of the urinary bladder. J Urol 1960;83:656–664.
18.
Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR: Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109:267.
19.
Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq E, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Parmentier C: Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992;15:631.
20.
Guo JZ, Gong LS, Chen SX, Luo BY, Xu MY: Malignant pheochromocytoma: Diagnosis and treatment in fifteen cases. J Hypertens 1989;7:261–266.
21.
Fischer M: Therapy of pheochromocytoma with 131I-metaiodobenzylguanidine. J Nucl Biol Med 1991;35:292–294.
22.
Castellani MR, Rottoli L, Maffioli L, Massimino M, Crippa F, Burragi GL: 131I-Metaiodobenzylguanidine therapy in paraganglioma. J Nucl Biol Med 1991;35:315–317.
23.
Stoba C, Skoczylas-Stoba B, Czauderna P: Clinical course and treatment of pheochromocytomas in children. Analysis of five cases. Eur J Pediatr Surg 1993;3:154–156.
24.
Galifer RB, Pous JG, Noblet D: Malignant pheochromocytoma. A case report in a 10-year-old boy with vertebral metastasis (in French). Chir Pédiatr 1982;23:121–124.
25.
Herrera LO, Hossain ZM, Rafal HS, Frelick RW, Ashley PF, Lopez GE: Malignant pheochromocytoma of the organ of Zuckerkandl: A study of 2 cases. J Surg Oncol 1980;14:133–145.
26.
Isaacson C, Rosenzqeig D, Seftel C: Malignant pheochromocytoma of the organ of Zuckerkandl. Arch Pathol 1960;70:725–729.
27.
Higgins P McR, Tresidder GC: Pheochromocytoma of the urinary bladder. Br Med J 1966;2:274–277.
28.
Goncalves E, Ninane J, Wese FX, Leonet J, Piret L, Cornu G, De Meyer R: Familial Pheochromocytoma: Successful treatment with 131I-MIBG. Med Pediatr Oncol 1990;18:126–130.
29.
Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G: Pheochromocytoma, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531–1638.
30.
Beljord C, Desclaux-Arramond F, Raffin-Sanson M, et al: The RET protooncogene in sporadic pheochromocytomas: Frequent MEN2-like mutations and new molecular defects. J Clin Endocrinol Metab 1995;80:2063–2068.
31.
Yoshimoto T, Naruse M, Zeng Z, Nishikawa T, Kasajima T, Toma H, Yamamori S, Matsumoto H, Tanabe A, Naruse K, Demura H: The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 1998;159:247–255.
32.
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH: Iodine-141-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J Nucl Med 1985;26:576–585.
33.
Kwekkeboom DJ, van Urk H, Pauw BKH, et al: Octreotide scintigraphy for detection of paragangliomas. J Nucl Med 1993;34:873–878.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.